Polydrug overdose mortality caused by synthetic opioids and stimulants: Current sex- and age- specific trajectories in national data (2018-2024)

Eduardo R. Butelman PhD[1], Yuefeng Huang PhD[1], Siri Shastry MD[2], Alex F. Manini MD[2], Rita Z. Goldstein PhD[1] and Nelly Alia-Klein PhD[1]

[1]Neuropsychoimaging of Addictions and Related Conditions, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York NY

[2]Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York NY

Corresponding Author:

Dr. Eduardo Butelman

Neuropsychoimaging of Addictions and Related Conditions,

Department of Psychiatry,

Icahn School of Medicine at Mount Sinai,

1 Gustave L. Levy Place,

New York, NY 10029-5674

Phone: (212)241-6127

E-mail: eduardo.butelman@mssm.edu

Abbreviations:

95%CI: 95% confidence intervals

AA: African American or Black

APC: annual percent change in rate of mortality; $((Rate_{Year\ N} - Rate_{Year\ N-1})/Rate_{Year\ N-1})$ X100%)

CDC: United States Centers for Disease Control and Prevention

F: Female

M: Male

MOR: mu-opioid receptor

MOUD: medications for opioid use disorder

NS: not significant

OD: overdose

SE: standard error

Abstract

Recent years have shown major increases in overdose (OD) mortality caused by *polydrug* exposure to synthetic opioids such as fentanyl and stimulants such as methamphetamine or cocaine. The goal of this study is to understand the trajectory and recent trends in this polydrug OD mortality, and how these are associated with decedents' sex and age. We carried out a cross-sectional analysis of national data for persons aged 15-74, from CDC WONDER for 2018-2024 (data for 2024 are currently considered provisional). The outcome measure was OD mortality rate/100,000 population; annual data for 2018-2024 were analyzed with joinpoint regression, and the most recent years (2023-2024) were analyzed with ANOVA and multiple linear regression. Males had greater polydrug OD mortality compared to females, across 2018-2024. Sex-specific joinpoint regressions detected increases in polydrug OD after 2018, then decreases from 2023 in males, and from 2022 in females. For polydrug OD, the annual percent change (APC) in 2024 versus 2023 was -37% and -31% in males and females, respectively. For synthetic opioids *without* stimulants, OD trends in 2024 versus 2023 were similar to those for polydrug OD (-41% and -38% APC in males and females, respectively). However, trends for stimulants *without* synthetic opioids showed relatively smaller changes (-3% APC in both sexes). Stratification into 10-year age groups for polydrug OD revealed that mortality peaked at age 35-44 and then declined at older ages. Recent decreases in polydrug OD mortality were observed across age groups, with joinpoints typically detected in 2022 or 2023. These findings indicate that after increases from 2018 onward, polydrug OD mortality caused by synthetic opioids and stimulants exhibited substantial decreases in both males and females in the most recent data available for 2024, and across a broad age range. Because relatively small changes were observed in OD mortality caused by stimulants *without* synthetic opioids in this time period, the decreases in polydrug OD mortality are more likely to be caused by changes in exposure, prevention or intervention strategies focused on opioids rather than on stimulants. While this polydrug OD mortality has decreased in 2024, it remains at concerning levels.

Introduction

The United States has undergone an epidemic of overdose (OD) mortality in recent years (e.g., 2018 onwards), exacerbated during the COVID pandemic[1–3]. These high OD rates are caused primarily by synthetic opioids such as the mu-opioid receptor (MOR) agonist fentanyl or its analogs[4], and by stimulants such as methamphetamine or cocaine[5–8]. Importantly, the current “fourth wave” of OD has shown increases in *polydrug* exposure to these two types of compounds[6,9,10]. For example, there was a 37% increase in the annual rate of nonfatal polydrug OD caused by opioids and amphetamines, for 2019 versus 2018[11]. In addition to the risk of *knowingly* using both opioids and stimulants[12,13], there has also been a concerning increase in OD due to the concealed addition of synthetic opioids such as fentanyl in the drug supply, including counterfeit oral formulations[14], as well as into other illicit formulations, which are then injected, inhaled or smoked[15]. This concealed presence of synthetic opioids can further increase the risk of OD morbidity and mortality[16–18].

Overdose morbidity and mortality caused by MOR agonists is principally due to respiratory depression[19,20], whereas those caused by stimulants (mediated principally through inhibition of monoamine neurotransmitter reuptake)[21,22] are due to different mechanisms, such as cardiovascular, neurovascular or neurological insults[23,24]. Opioid OD are acutely managed by administration of MOR antagonists such as naloxone (or nalmefene). Notably, naloxone has become more widely available in 2023-2024, due to the approval of several over-the-counter intranasal formulations, expanding accessibility in the community, compared to prior years[25,26]. Furthermore, receipt of medications for opioid use disorder (MOUD, such as chronic buprenorphine or methadone) also provides increased safety and decreased OD events, although MOUD receipt and adherence can vary based on social determinants of health[27–29]. In recent years there has also been increased emphasis on “low threshold” referrals for MOUD[28,30], as well as initiation of this treatment in emergency settings[31]. By contrast, there are no medical countermeasures or antidotes specifically approved for OD caused by methamphetamine or cocaine. Also, while some preclinical studies have delineated some acute pharmacological interactions between synthetic opioids and stimulants (e.g., on respiratory depression)[32], the pathophysiological mechanisms underlying morbidity and mortality in such polydrug OD are not fully understood at the clinical level[9].

Overall, it is therefore important to focus on the latest trajectory of OD caused by polydrug synthetic opioid and stimulant exposure, as this combination has not been directly examined in recent studies[33,34]. Furthermore, it is important to examine how the changes in polydrug OD mortality occurs based on major individual differences variables such as sex and age, which we and others have shown to be highly relevant to this risk[5,33].

Methods:

This study used de-identified publicly available data on “multiple cause mortality”, from the CDC WONDER platform for 2018-2024 (https://wonder.cdc.gov/mcd.html). The Institutional Review Board of the Icahn School of Medicine at Mount Sinai certified that this study is not considered Human Subjects Research, and is thus exempt from its review requirements. As part of confidentiality protections, data that were “suppressed” (due to n < 10 per cell) or deemed “unreliable” in CDC WONDER were excluded from analysis. Data for 2024 are considered provisional at the time of downloading (June 2025). The overall age range studied was 15-74, due to low prevalence at younger and older ages. This observational study followed STROBE reporting guidelines (see supplement). The overall level of significance, alpha, was set at the p=0.05 level.

Data set

The main outcome variable was age-adjusted death rate per 100,000 population. We examined ICD-10 codes for overdoses (unintentional X40-X44, suicide X60-X64, homicide X85, and undetermined intents Y10–Y14). Data were obtained for three drug categories: “other synthetic narcotics” (“synthetic opioids hereafter; this predominantly reflects fentanyl and its analogs, but also compounds from other chemical scaffolds; T40.4)[19,35], psychostimulants with abuse potential (which predominantly reflects methamphetamine but also includes its analogs; T43.6), and cocaine (T40.5). Data were stratified by sex for the main analyses. In follow-up comparisons we also examined the two largest racial groups (White and African American or Black) in stratified analyses for synthetic opioid and stimulant polydrug overdoses. A further follow-up also stratified six consecutive 10-year age groups (i.e., 15–24, 25–34, 35–44, 45–54, 55–64 and 65–74). When this age stratification was carried out, analyses were based on crude rates.

Data analyses:

Annual data were obtained initially for polydrug OD mortality caused by synthetic opioids and stimulants, by searching: "Other synthetic narcotics" (i.e., synthetic opioids, ICD-10 code T40.4) *AND* ["Psychostimulants with abuse potential" (T43.6), *OR* cocaine (T40.5)]; this latter composite category is termed "stimulants" hereafter, for brevity. The CDC WONDER platform does not have a "*NOT"* search function, therefore in order to examine OD that were caused by synthetic opioids *without* stimulants (and vice versa), we carried out the following re-calculations, based on a simple Boolean strategy:

Group a) Synthetic opioids without stimulants *= [Synthetic opioid] - [Polydrug Synthetic opioid + Stimulant]*

Group b) Stimulants without synthetic opioids *= [Stimulant] - [Polydrug Synthetic opioid + Stimulant]*

Whenever relevant, standard errors (SE) for rates/100,000 for Groups a) and b) above were calculated with a Poisson approximation: $SE = 100{,}000 / N_{Population} * \sqrt{[OD\ counts_{Group\ a} + OD\ counts_{Group\ b}]}$.

Joinpoint Analysis: Joinpoint Regression software (V 5.4.0)[36] from the National Cancer Institute was used to examine annual trends in log-transformed age-adjusted overdose mortality rates (per 100,000). The technique was used to determine trends across years in a data-driven manner, by detecting "joinpoints" when a significant change occurs. Jointpoint regression examines annual percent change (APC) in the rate of OD for consecutive years ($APC = ((Rate_{Year\ N} - Rate_{Year\ N-1})/Rate_{Year\ N-1})\ X100\%$). Thus, a positive APC value indicates an increase in OD mortality over consecutive years, and a negative APC indicates a decrease. The joinpoint regression parameters were as follows: We set the maximum number of possible joinpoints=2, taking into consideration the number of years under study[37]. The first order autocorrelation option was used to account for dependence of time series data. The Bayesian Information Criterion was used to select the number of joinpoints (i.e., 0-2) in the optimal model. The empirical quantile method[38] was used to calculate 95%CI for the APC, with 5001 resamples and a seed=10000.

Follow-ups and sub-group analyses:

a) Focus on the most recent data: OD mortality rates in 2024, and annual percent changes in OD mortality in 2024 versus 2023 were initially examined, with 2-way ANOVA (sex X type of drug), using US census division - level data, after examining normality with the D'Agostino-Pearson test and checking quantile-quantile plots (Graphpad Prism V10.5.0). These ANOVAs used the Greenhouse-Geisser correction for violations of sphericity. In order to examine if major sociodemographic variables and public health interventions[39] were associated with state-level annual percent change in polydrug OD mortality rates for 2023-2024, we carried out an ordinary-least squares multiple linear regression, with asymmetric profile-likelihood 95%CI for the parameters. The predictor variables were sex (with females as the reference category), and z-score transformed values for prescribed naloxone dispensing rate per 100 persons (2023 CDC data)[40], and the following major social determinants of health, based on state-level data from the US Census Bureau's American Community Survey from 2023[41]: median household income based on census, OD rates in 2023, %of population which is African-American or Black, and % of population without health insurance. Utility of simpler regression models was evaluated with the Akaike Information Criterion. In this analysis, data from the following states were excluded, due to data suppression or unreliable estimates: Hawaii, Montana, Nebraska, New Hampshire, North Dakota, South Dakota, Vermont and Wyoming.

b) Stratification by age: In a followup examining national data in 10-year age groups (overall age range 15-75), the above joinpoint procedure was also used for 2018-2024, examining crude rates.

c) Stratification by race: We carried out stratified joinpoint analyses as above, for the two largest racial groups in national data (African-American/Black and White).

Results

Demographics and mortality rates: Supplementary Table S1A-C shows the number of OD deaths caused by the drug types under study, together with crude rates and age-adjusted rates, stratified by sex and year. Overall, males had approximately 2-fold greater overdose rates compared to females across the three drug types causing the OD, and years under study.

Joinpoint regressions of national data: We first examined sex-specific trajectories with joinpoint regressions (Fig. 1 and Table 1), which yielded differences across drug type and sex. **Polydrug OD caused by synthetic opioids *and* stimulants:** In males, there was an initial increase in OD from 2018, with two joinpoints (2020 and 2023), followed by a decrease in 2024. In females, there was also an increase from 2018, with a single joinpoint in 2022. **Synthetic opioids *without* stimulants:** In males, there was an initial increase in OD from 2018, with two joinpoints (2020 and 2023), showing a period of relative stability (possible plateau), followed by a decrease in 2024. In females, there was also an increase from 2018, with a single joinpoint in 2021, and a decrease thereafter. **Stimulants *without* synthetic opioids:** For both males and females, there was only one joinpoint (2021), indicating an increase in OD mortality in 2018-2021, followed by a decrease in 2021-2024. Of note, the magnitude of the APC was smaller for stimulants *without* synthetic opioids, compared to the two other drug types, indicating relative stability across 2018-2024 of OD caused by stimulants without synthetic opioids, compared to the former two groups (see Fig. 1).



Figure 1: Age-adjusted overdose (OD) mortality rates / 100,000 census population for 2018-2024 for males and females (A-B, respectively). *Note different Y-axis ranges in the two panels.* Regression lines are based on optimal joinpoint regression results (see Table 2). Standard error (SE) bars typically fall within the symbols. Filled symbols indicate the "joinpoints" for each type of overdose based on the optimal models (i.e., the year in which a change in trend is observed). Full data are in Supplement Table S1A-C.

Table 1: Joinpoint regression optimal models in annual overdose mortality rates (per 100,000; age adjusted). Models illustrated in Fig. 2.

1A: Polydrug: Synthetic opioids *and* stimulants									
	Trend 1			Trend 2			Trend 3		
	Years	APC* (95%CI)	P-value	Years	APC (95%CI)	P-value	Years	APC (95%CI)	P-value
Males	2018-2020	58.6 (17.7 - 305.0)	p= 0.013	2020-2023	18.7 (9.3 - 43.3)	p=0.008;	2023-2024	-43.1 (-69.3 - -16.7)	p=0.0004;
Females	2018-2022	37.2 (23.5 - 88.2)	p< 0.000001	2022-2024	-20.0 (-63.8 - 2.5)	NS	N/A: only 2 trends in optimal model		

*APC: Annual percent change; positive values indicate increases in year-to-year in OD mortality, negative values indicate a decrease; see Methods

1B: Synthetic opioids *without* stimulants									
	Trend 1			Trend 2			Trend 3		
	Years	APC* (95%CI)	P-value	Years	APC (95%CI)	P-value	Years	APC (95%CI)	P-value
Males	2018-2020	35.0 (23.3 - 90.8)	p< 0.000001	2020-2023	-0.6 (-8.1 - 13.0)	NS;	2023-2024	-47.7 (-66.1 - -27.4)	p< 0.000001;
Females	2018-2021	26.3 (14.4 - 46.9),	p< 0.000001;	2021-2024	-17.6 (-33.0 - -8.3)	p=0.0004;	N/A: only 2 trends in optimal model		

1C: Stimulants *without* synthetic opioids									
	Trend 1			Trend 2			Trend 3		
	Years	APC* (95%CI)	P-value	Years	APC (95%CI)	P-value	Years	APC (95%CI)	P-value
Males	2018-2021	8.5 (8.1 - 8.9)	p< 0.000001;	2021-2024	-3.9 (-4.3 - -3.6)	p< 0.000001;	N/A: only 2 trends in optimal model		
Females	2018-2021	7.3 (4.1 - 12.8)	p< 0.000001;	2021-2024	-4.9 (-12.7 - -1.8)	p=0.0028;	N/A: only 2 trends in optimal model		



Figure 2: A. Age-adjusted overdose mortality rates in the most recent year (2024) in males and females, based on census division - level data. **B.** Annual percent change (APC) in 2024 versus 2023. Full data in Table S2A-C

Overdoses mortality in the most recent year, 2024: We followed up the above analyses with a focus on the last year available (2024; provisional data), using census division - level data (full data with individual census division in Table S2A-C). A 2-way ANOVA for 2024 (Figure 2A) showed main effects of sex and of drug type, and no significant sex X drug interaction. Tukey tests show that polydrug OD rates in 2024 were greater than those caused by the two other categories (which did not differ from each other). This finding held in both males and females.

Examination of APC data for 2024 versus 2023: There were greater decreases in OD mortality in the polydrug and synthetic opioid without stimulant groups, compared to the stimulant without synthetic opioid group (Fig. 2B). Thus, a 2-way ANOVA using census division-level data detected a significant main effect of drug type, but no effect of sex or sex X drug interaction (Fig. 2B). Post hoc Sidak tests show that there was a greater decrease in OD rates in 2024 vs 2023 for the polydrug OD, and synthetic opioid without stimulant groups, versus the stimulant without synthetic opioid group, both in males and females.

Multivariable adjusted model for annual percent change in polydrug overdoses in 2024 versus 2023: We then extracted state-level OD data (Table S3) and sociodemographic data (Table S4), and carried out a univariate Spearman correlation matrix (Table S5) for an initial univariate exploration. This was followed by a

multiple linear regression, with state-level APC data for 2024 versus 2023 as the outcome (e.g., Fig 2B), with a multiple linear regression, adjusting for sociodemographic variables. These predictor variables explained a substantial proportion of the variance in the outcome variable (R^2=0.36; df=79). As shown in Table 2, sex, state-level naloxone dispensing rates and OD rate were not significant predictors of APC, indicating that the APC in 2024 versus 2023 were not associated with the OD rate at baseline (i.e., 2023). However, greater household income, and greater %of persons without health insurance were positive predictors of APC (indicating lesser decreases in OD rates). Greater %African-American or Black population was a negative predictor of APC (indicating greater decreases in OD rates). Simpler models (e.g., without median household income), were less preferred, based on the Akaike Information Criterion (not shown).

Table 2: Multiple linear regression for annual percent change in mortality for polydrug OD from 2024 versus 2023, studying sex and state-level predictors.

Variable	**Beta Estimate**	**95% CI (profile likelihood)**	**P value**
Intercept	-31.72	-35.29 to -28.14	<0.0001
Sex (Male; Female as reference	-8.405	-17.67 to 0.86	0.075; NS
State-level naloxone dispensing rate/100 (2023)	-1.16	-3.79 to 1.47	0.38; NS
State-level median household income ($)	5.29	2.54 to 8.04	0.0003
State-level % without health insurance coverage	6.30	3.44 to 9.15	<0.0001
State-level %Population that is African-American / Black	-4.84	-7.38 to -2.28	0.0003
State-level OD rate/100,000 (2024)	0.12	-0.15 to 0.38	0.39; NS

Age stratification of polydrug OD mortality in 2018-2024: We stratified crude mortality data in consecutive 10-year age groups (overall age range 15-74; Fig. 3), and carried out separate joinpoint analyses in males and females. There was a biphasic pattern of age-related mortality across the years, with relatively low levels in the youngest age group (15-24), increasing until age 35-44, and then declining gradually from 45-54 to 65-74; this overall pattern was observed both in males and females. Sex differences (M>F) were generally observed at each age group, and across years. The number and years of joinpoints differed across males versus females, indicating sex differences in the trajectories of these polydrug OD. Full data and jointpoint regression results are in Table S6.



Figure 3: Crude OD mortality rates / 100,000 for 2018-2024 for males and females across 10-year age groups, (A-F). Some standard error bars fall within the symbols. Lines are based on optimal joinpoint regression results; filled symbols indicate the optimal "joinpoints". Full data are shown in Table S6.

Race stratification of polydrug OD mortality in 2018-2024: We carried out sex-stratified joinpoint analyses for the two most prevalent race categories in national data (African-American/Black and White). Peak mortality occurred in 2022-2023. While there were greater peak OD rates of persons in the African-American/Black category versus white, the APC in 2024 versus 2023 were similar. For example, in males there was a calculated APC of -49% [95%CI: -20% - -71%] for persons in the African-American/Black category, and -42% [95%CI: -20% - -56%] in the white category (data not shown).

Discussion

Polydrug OD caused by synthetic opioids and stimulants have reached epidemic proportions in recent years[6,42]. In this national cross-sectional study, joinpoint regression was used for the first time to examine the trajectory of this polydrug OD mortality for 2018-2024. This analysis detected increases in polydrug OD mortality after 2018, until 2023 in males and 2022 in females, and declines thereafter. Focusing more directly on the most recent trends (i.e., 2024 versus 2023), relatively large decreases were observed in this polydrug mortality (i.e., -36% and -31% APC in males and females, respectively). Similar decreases were detected in 2024 versus 2023 for OD caused by synthetic opioids *without* stimulants (i.e., -42% and -39% APC in males and females, respectively), whereas smaller changes were observed for OD caused by stimulants without synthetic opioids (i.e., -3% and -2% APC in males and females, respectively). This result suggests that recent decreases in OD mortality for these types of compounds may be due primarily to changes in exposure, and/or public health prevention and intervention strategies focusing on synthetic opioids[28,43,44], while less robust changes are observed on OD mortality caused by stimulants.

We and others have shown robust sex differences in synthetic opioid or stimulant OD, where males have greater mortality across jurisdictions and environments[5,8]. In this study, males had approximately 2-fold greater polydrug mortality than females overall, even across dynamic yearly trends in 2018-2024. Intriguingly, whereas rates of polydrug OD mortality differed in males versus females, an adjusted analysis did not detect sex as a significant predictor of change across years (i.e., APC), indicating that recent decreases in mortality did not differ in males versus females. In this adjusted analysis, we also found that the rate of prescribed naloxone dispensing[40] was not a significant predictor of these changes in the polydrug OD (of note these data did not include over-the-counter naloxone sales, to be examined in the future)[25,45]. Importantly, the

adjusted analysis did detect that a lesser decrease in these polydrug OD occurred in states that had a greater percentage of the population without health insurance, adjusting for household income. This result suggests that availability of continuing care is associated with better public health outcomes, even for acute emergencies such as OD.

Synthetic opioid or stimulant OD mortality has also been shown to differ by age, with peak mortality typically observed in mid-adulthood[5,33]. This study provides the first age stratification for national polydrug OD across 2018-2024, and shows large differences in mortality across the lifespan, with highest risk at ages 35-44, observable in both males and females. Nevertheless recent decreases in polydrug OD rates were observed even for this age group, based on joinpoint regressions.

Race is an important social determinant of health, including for risk of OD mortality[5,39]. In a follow-up, we found that while polydrug OD rates differed across persons in the African-American/Black racial group versus those in the white group, there were similar annual percent changes (i.e., decreases) in 2024 versus 2023. This suggests that recent decreases in these polydrug OD were observed across major social determinants of health such as race.

Limitations: This national study has considerable strengths, but some limitations need to be considered. **A)** The ICD-10 category for synthetic opioids is thought to reflect primarily fentanyl and its analogs[4], but can also contain MOR-agonists from other chemical scaffolds[35]. Also, we did not study other types of MOR-agonists available for analysis in CDC WONDER (e.g., heroin, methadone or prescription opioids), as these are causing OD at a substantially lower rate than synthetic opioids, in recent years[5,46]. **B)** The "psychostimulants with abuse potential" ICD-10 category may primarily reflect methamphetamine, but presence of other amphetamine analogs or stimulants cannot be excluded. Also, for simplicity, we examined compounds such as methamphetamine and cocaine together, but their pathophysiological effects are not necessarily identical[47,48]. **C)** The data for 2024 are considered provisional at the time of this submission. However, there is relatively high completeness in CDC WONDER data after 6 months of occurrence[49], and the data for this study were obtained after such an interval (i.e., in June 2025). There may also be potential under-reporting or mis-reporting of OD mortality in death certificates[50,51]. **D)** For simplicity, we did not examine further polydrug patterns (e.g., including benzodiazepines, alcohol or xylazine)[52,53].

Implications and conclusions: This study provides sex-specific national trajectories of mortality for polydrug OD caused by synthetic opioids and stimulants in 2018-2024, relevant to the national OD crisis. Overall, relatively large decreases in this polydrug OD mortality were detected in 2024 versus 2023, similarly for males and females. However, joinpoint regressions indicate that trajectories of polydrug OD mortality across the broader 2018-2024 time period were not identical across sex, for reasons that should be examined. Furthermore, we also found that OD mortality caused by opioids *without* stimulants underwent a similar recent decrease in 2024, consistent with recent reports[33]. However, considerably smaller changes occurred in OD caused by stimulants *without* synthetic opioids. In addition, our age stratification analyses also show that while decreases in polydrug OD mortality were observed across a broad age range (overall range 15-74), persons in mid-adulthood remain at highest risk[54–56]. Overall, despite these recent decreases, polydrug OD rates in 2024 are still greater than those for the two other groups studied here, indicating that development of targeted prevention and intervention strategies is a continuing need[13,18,57]

Competing Interests: The authors have no conflicts to declare.

Author Contributions:

Concept and Design: ERB

Data acquisition: publicly available de-identified data from CDC WONDER

Analysis: ERB

Interpretation and writing: All authors

Funding: The authors gratefully acknowledge funding from NIDA-NIH DA5U01DA053625 (ERB), 2R01DA048009 (AM), 1R01DA060914 (RZG), 5R01DA049547 (NAK, RZG). The funder had no role in the design, drafting or editing of the project.

References

1. Han B, Einstein EB, Jones CM, Cotto J, Compton WM, Volkow ND. Racial and Ethnic Disparities in Drug Overdose Deaths in the US During the COVID-19 Pandemic. JAMA Netw Open. 2022;5:e2232314.
2. Brown KG, Chen CY, Dong D, Lake KJ, Butelman ER. Has the United States Reached a Plateau in Overdoses Caused by Synthetic Opioids After the Onset of the COVID-19 Pandemic? Examination of Centers for Disease Control and Prevention Data to November 2021. Front Psychiatry. 2022;https://www.frontiersin.org/articles/10.3389/fpsyt.2022.947603/full.
3. Ciccarone D. Bending the overdose curve — still not enough. N Engl J Med. 2024;391:1052–1053.
4. Amaducci A, Aldy K, Campleman SL, Li S, Meyn A, Abston S, et al. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Netw Open. 2023;6:e2331264.
5. Butelman ER, Huang Y, Epstein DH, Shaham Y, Goldstein RZ, Volkow ND, et al. Overdose mortality rates for opioids and stimulant drugs are substantially higher in men than in women: state-level analysis. Neuropsychopharmacology. 2023. 15 June 2023. https://doi.org/10.1038/s41386-023-01601-8.
6. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34:344–350.
7. Tanz LJ, Dinwiddie AT, Mattson CL, O'Donnell J, Davis NL. Drug Overdose Deaths Among Persons Aged 10-19 Years - United States, July 2019-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71:1576–1582.
8. Wilson N, Kariisa M, Seth P, Smith H 4th, Davis NL. Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020;69:290–297.
9. Shastry S, Shulman J, Aldy K, Brent J, Wax P, Manini AF, et al. Psychostimulant drug co-ingestion in non-fatal opioid overdose. Drug Alcohol Depend Rep. 2024;10:100223.
10. CDC. The Fentalog Study: A Subset of Nonfatal Suspected Opioid-Involved Overdoses with Toxicology Testing. Overdose Prevention. 2024. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/fentalog-study-dashboard.html. Accessed 20 June 2025.
11. Liu S, Scholl L, Hoots B, Seth P. Nonfatal drug and polydrug overdoses treated in emergency departments - 29 states, 2018-2019. MMWR Morb Mortal Wkly Rep. 2020;69:1149–1155.
12. Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87:39–45.
13. Cotten JF. Goofball polypharmacy. J Pharmacol Exp Ther. 2024;388:241–243.
14. Volkow ND, Califf RM, Sokolowska M, Tabak LA, Compton WM. Testing for Fentanyl - Urgent Need for Practice-Relevant and Public Health Research. N Engl J Med. 2023. 10 June 2023. https://doi.org/10.1056/NEJMp2302857.
15. Karandinos G, Unick J, Ciccarone D. Mortality risk among individuals who smoke opioids compared with those who inject: A propensity score-matched cohort analysis of United States national treatment data. Addiction. 2025. 22 January 2025. https://doi.org/10.1111/add.16740.
16. Glidden E, Gladden RM, Dion C, Spyres MB, Seth P, Aldy K, et al. Suspected counterfeit M-30 oxycodone pill exposures and acute withdrawals reported from a single hospital - Toxicology Investigators Consortium Core Registry, U.s. census Bureau Western Region, 2017-2022. MMWR Morb Mortal Wkly Rep. 2024;73:642–647.
17. Allen C, Arredondo C, Dunham R, Fishman M, Lev L, Mace S, et al. Guidance for Handling the Increasing Prevalence of Drugs Adulterated or Laced With Fentanyl. PS. 2023;74:1059–1062.
18. Friedman J, Ciccarone D. The public health risks of counterfeit pills. Lancet Public Health. 2025;10:e58–e62.
19. Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2021:108019.
20. Baldo BA. Opioid-induced respiratory depression: clinical aspects and pathophysiology of the respiratory network effects. Am J Physiol Lung Cell Mol Physiol. 2025;328:L267–L289.
21. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–1223.
22. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995;15:4102–4108.
23. Richards JR, Laurin EG. Methamphetamine toxicity. StatPearls, Treasure Island (FL): StatPearls Publishing; 2025.

24. Heard K, Palmer R, Zahniser NR. Mechanisms of acute cocaine toxicity. Open Pharmacol J. 2008;2:70–78.
25. FDA approves first over-the-counter naloxone nasal spray. US Food and Drug Administration. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray. Accessed 5 June 2025.
26. Bennett AS, Freeman R, Des Jarlais DC, Aronson ID. Reasons people who use opioids do not accept or carry no-cost naloxone: Qualitative interview study. JMIR Form Res. 2020;4:e22411.
27. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3:e1920622.
28. Shastry S, Carpenter J, Krotulski A, Brent J, Wax P, Aldy K, et al. Disparities in treatment and referral after an opioid overdose among emergency department patients. JAMA Netw Open. 2025;8:e2518569.
29. Hooker SA, Starkey C, Bart G, Rossom RC, Kane S, Olson AW. Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings. BMC Prim Care. 2024;25:361.
30. Wakeman SE, McGovern S, Kehoe L, Kane MT, Powell EA, Casey SK, et al. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic. J Subst Abuse Treat. 2022;141:108848.
31. D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency Department-Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Clinical Trial. JAMA. 2015;313:1636–1644.
32. Hiranita T, Ho NP, France CP. Ventilatory effects of fentanyl, heroin, and d -methamphetamine , alone and in mixtures, in male rats breathing normal air. J Pharmacol Exp Ther. 2023. 22 September 2023. https://doi.org/10.1124/jpet.123.001653.
33. Post LA, Ciccarone D, Unick GJ, D'Onofrio G, Kwon S, Lundberg AL, et al. Decline in US drug overdose deaths by region, substance, and demographics. JAMA Netw Open. 2025;8:e2514997.
34. Kiang MV, Humphreys K. Recent drug overdose mortality decline compared with pre-COVID-19 trend. JAMA Netw Open. 2025;8:e2458090.
35. Berger JC, Severe AD, Jalloh MS, Manini AF. Naloxone dosing and hospitalization for nitazene overdose: A scoping review. J Med Toxicol. 2025. 4 February 2025. https://doi.org/10.1007/s13181-025-01059-8.
36. Joinpoint Regression Program. https://surveillance.cancer.gov/joinpoint. Accessed 10 June 2025.
37. Ingram DD, Malec DJ, Makuc DM, Kruszon-Moran D, Gindi RM, Albert M, et al. National Center for Health Statistics guidelines for analysis of trends. Vital Health Stat 2. 2018:1–71.
38. Kim H-J, Chen H-S, Byrne J, Wheeler B, Feuer EJ. Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact. Stat Med. 2022;41:3102–3130.
39. Social Determinants of Health. https://odphp.health.gov/healthypeople/priority-areas/social-determinants-health. Accessed 12 February 2025.
40. CDC. Naloxone dispensing rate maps. Overdose Prevention. 2024. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/naloxone-dispensing-rate-maps.html. Accessed 5 June 2025.
41. U.S. Census Bureau. Explore Census Data. https://data.census.gov/advanced. Accessed 16 June 2025.
42. Hedegaard H, Miniño AM, Warner M. Co-involvement of opioids in drug overdose deaths involving cocaine and psychostimulants; https://doi.org/10.15620/cdc:103966. NCHS Data Brief, No 406 Hyattsville, MD: National Center for Health Statistics 2021. 2021. http://dx.doi.org/10.15620/cdc:103966.
43. Volkow N, Dye LR. Groundbreaking research from NIDA addressing the challenges of the opioid epidemic. J Med Toxicol. 2025;21:69–77.
44. Levengood TW, Shaw LC, Zang X, Schackman BR, Walley AY, Urquhart C, et al. A geospatial analysis of naloxone distribution patterns in the Massachusetts overdose education and naloxone distribution program (MA OEND). Drug Alcohol Depend. 2025;274:112783.
45. Marley GT, Annis IE, Egan KL, Delamater P, Carpenter DM. Naloxone Availability and Cost After Transition to an Over-the-Counter Product. JAMA Health Forum. 2024;5:e241920.
46. Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs. JAMA Psychiatry. 2022. 2022. https://doi.org/10.1001/jamapsychiatry.2022.1776.
47. Zimmerman JL. Cocaine intoxication. Crit Care Clin. 2012;28:517–526.
48. Curran L, Nah G, Marcus GM, Tseng Z, Crawford MH, Parikh NI. Clinical Correlates and Outcomes of Methamphetamine-Associated Cardiovascular Diseases in Hospitalized Patients in California. J Am Heart

Assoc. 2022;11:e023663.
49. December . Vital Statistics Rapid Release. https://www.cdc.gov/nchs/data/vsrr/report001.pdf. Accessed 12 June 2025.
50. Johnson SC, Cunningham M, Dippenaar IN, Sharara F, Wool EE, Agesa KM, et al. Public health utility of cause of death data: applying empirical algorithms to improve data quality. BMC Med Inform Decis Mak. 2021;21:175.
51. Boslett AJ, Denham A, Hill EL. Using contributing causes of death improves prediction of opioid involvement in unclassified drug overdoses in US death records: Methods for predicting fatal opioid overdoses. Addiction. 2020;115:1308–1317.
52. Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, et al. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol . 2023;61:173–180.
53. Friedman JR. Assessing an ICD-10 code approach for estimating xylazine-involved overdose deaths in the United States. Drug Alcohol Depend. 2025;274:112781.
54. Butelman ER, Chen CY, Brown KG, Kreek MJ. Escalation of drug use in persons dually diagnosed with opioid and cocaine dependence: Gender comparison and dimensional predictors. Drug Alcohol Depend. 2019;205:107657.
55. Woodcock EA, Lundahl LH, Stoltman JJ, Greenwald MK. Progression to regular heroin use: examination of patterns, predictors, and consequences. Addict Behav. 2015;45:287–293.
56. Rodriguez-Cintas L, Daigre C, Grau-Lopez L, Barral C, Perez-Pazos J, Voltes N, et al. Impulsivity and addiction severity in cocaine and opioid dependent patients. Addict Behav. 2016;58:104–109.
57. Lim TY, Dong H, Stringfellow E, Hasgul Z, Park J, Glos L, et al. Temporal and spatial trends of fentanyl co-occurrence in the illicit drug supply in the United States: a serial cross-sectional analysis. Lancet Reg Health Am. 2024;39:100898.